Shionogi Pharma Prepares to Begin Integration of Management

 Shionogi Pharma Co., Ltd. (Head Office: Settsu, Osaka, Japan; President & CEO: Ryuichi Kume) (hereafter “Shionogi Pharma”) today announces the company has decided in its Board of Directors’ meeting on July 2, 2021 to begin preparations for integration of management with its wholly owned subsidiary Nagase Medicals Co., Ltd. (Head Office: Itami, Hyogo, Japan; Representative Director and President: Mitsuru Akasaka) (hereafter “Nagase Medicals”), aiming for completion of the integration by April 1, 2022.

 The detailed contents of the integration will continue to be published the assumption that all necessary Board of Directors’ and relevant government approvals will be obtained.

1.　Purpose of Integration

 Shionogi Pharma has expanded its business of manufacturing, sale, analytical testing and pharmaceutical engineering of medicinal drugs and investigational drugs under its mission to “promote health and create new value to benefit all of society, providing highly valued healthcare products and services through the development of new technologies”. In addition, we aim to become the most trusted one-stop CDMO (Contract Development and Manufacturing Organization) meeting the needs of all our customers, not limited to the Shionogi group. Nagase Medicals is involved in the development and manufacture of medical drugs and has also expanded into the contract manufacture of highly potent injectable pharmaceuticals.

 The integration of the management of the two businesses aims to create a faster and higher quality full-range CDMO and solutions business to increase our customer value offering and promote our growth as a technological innovation-focused manufacturing company. Through establishing a new business foundation, we will strive to create a diverse modality CDMO solution based on key strengths in manufacturing technology for high pharmacological activity API, solid and injectable, while also aiming to establish a new continuous manufacturing platform for API to pharmaceuticals by leveraging our unique knowledge, technology, experience and talent.

2.　Integration Schedule and Planning

 The companies will begin drafting integration plans to target an April 1, 2022 integration date under the assumption that all necessary approvals from the relevant authorities will be acquired without issue and in a timely manner. We will continue to affect preparations to discuss and determine detailed integration methodology and scheduling towards the target integration date.

For further information, contact:

Shionogi Pharma Co., Ltd., Corporate Planning Department

TEL：+81-6-6381-7402